Related Experiment Videos
Expression of the SART1 tumor-rejection antigen in human osteosarcomas
1Departments of Orthopaedic Surgery and Immunology, Kurume University School of Medicine, Japan.
Abstract:
We recently reported a tumor-rejection antigen, SART1259, possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs). This study investigated the expression of SART1259 antigen in osteosarcoma and other skeletal malignant tumors to explore for a potential molecule for use in specific immunotherapy. The SART1259 antigen was detected in the cytosol fraction of 13 of 21 (62%) osteosarcoma cell lines and 3 of 8 (38%) osteosarcoma tissues, and 3 of 10 (30%) malignant fibrous histiocytoma (MFH) tissues. The HLA-A24+ and SART1259+ osteosarcoma cells were recognized by the HLA-A24 restricted and SART1 specific CTLs. These results raise a possibility that the SART1259 would be an appropriate molecule for use in specific immunotherapy of approximately one-third of HLA-A24+ patients with osteosarcoma and MFH.
Insights
The SART1259 antigen shows potential for specific immunotherapy in osteosarcoma and malignant fibrous histiocytoma. This tumor antigen was detected in a significant portion of these skeletal cancers, suggesting its utility in targeted therapies.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cytotoxic T lymphocytes (CTLs) are crucial for tumor rejection.
- Tumor-rejection antigens like SART1259 present epitopes that can stimulate CTL responses.
- Specific immunotherapy aims to harness the immune system to target cancer cells.
Purpose of the Study:
- To investigate the expression of the SART1259 antigen in osteosarcoma and other skeletal malignancies.
- To evaluate SART1259 as a potential target for specific immunotherapy.
- To determine the prevalence of SART1259 expression in relevant cancer types.
Main Methods:
- Detection of SART1259 antigen in osteosarcoma and malignant fibrous histiocytoma (MFH) cell lines and tissues using biochemical assays.
- Analysis of SART1259 expression in relation to HLA-A24 status.
- Assessment of SART1259-specific CTL recognition of tumor cells.
Main Results:
- SART1259 antigen was detected in 62% of osteosarcoma cell lines and 38% of osteosarcoma tissues.
- The antigen was also found in 30% of malignant fibrous histiocytoma tissues.
- HLA-A24 positive and SART1259 positive osteosarcoma cells were recognized by SART1-specific CTLs.
Conclusions:
- SART1259 is expressed in a notable subset of osteosarcoma and MFH.
- SART1259 represents a potential target for specific immunotherapy in approximately one-third of HLA-A24 positive patients with these cancers.
- Further research into SART1259-based immunotherapies is warranted.